Avenira (ASX:AEV) received further investment commitment from shareholder Hebang Biotechnology Investment, a unit of Sichuan Hebang Biotechnology, according to a Monday filing with the Australian bourse.
The investment consists of an AU$7.6 million placement, through the issue of 1.1 billion shares at AU$0.007 apiece, subject to shareholder and regulatory approvals, increasing Hebang's interest in the company to 49%, the filing said.
Pending these approvals, Hebang has also agreed to provide an unsecured drawdown loan facility priced at nearly AU$7.6 million also subject to approval, the filing added.
The loan will have a minimum drawdown of AU$2 million per tranche and will accrue interest at 12% per annum, payable upon completion of the placement, the company said.
The funds from both the placement and the loan will be used to advance the company's direct shipping ore project and for general working capital purposes, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。